Novo Nordisk names VP national diabetes sales, managed care and government accounts

PRINCETON, N.J. A Denmark-based drug maker has appointed a new executive to head diabetes sales in the United States.

Novo Nordisk announced Feb. 17 that it had appointed Andy Ajello as VP national diabetes sales, managed care and government accounts. Ajello will report directly to Jerzy Gruhn, president of the company's North American division. 

Ajello had served as associate VP diabetes sales for the eastern area, leading more than 600 other employees; in his new position, he will lead 2,000. He began working for Novo Nordisk in 2001, helping to launch NovoLog (insulin aspart [rDNA origin] injection). 

"In his eight years at Novo Nordisk, Andy has developed an impressive track record for building high-performing field sales teams," Gruhn said in a statement. "His focus on cross-functional collaboration, quick decision making and strategic execution will help us continue our growth and ultimately realize our ambition of changing diabetes."